Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection

Journal of Hepatology

Volumn 66, Issue 6, 2017, Pages 1282-1299

  Ramos Casals, Manuel ^a,b,c   Zignego, Anna Linda ^d   Ferri, Clodoveo ^e   Brito Zerón, Pilar ^a,b,f   Retamozo, Soledad ^a,g   Casato, Milvia ^h   Lamprecht, Peter ⁱ   Mangia, Alessandra ^j   Saadoun, David ^k,l,m   Tzioufas, Athanasios G ⁿ   Younossi, Zobair M ^o   Cacoub, Patrice ^k,l,m  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f Hospital CIMA Sanitas   (Spain)

^g HOSPITAL PRIVADO   (Argentina)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF LÜBECK   (Germany)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k SORBONNE UNIVERSITÉ   (France)

^l Unit of Dermatology   (France)

^m PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁿ UNIVERSITY OF ATHENS   (Greece)

^o BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

more..

Author keywords

DAAs; Extrahepatic manifestations; Hepatitis C virus; Rituximab

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; RITUXIMAB;

ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CHRONIC HEPATITIS C; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; HUMAN; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA EXCHANGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; SYSTEMATIC REVIEW (TOPIC); COMPLICATION; CONSENSUS DEVELOPMENT; CRYOGLOBULINEMIA; EVIDENCE BASED MEDICINE; VASCULITIS;

ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; CRYOGLOBULINEMIA; EVIDENCE-BASED MEDICINE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LYMPHOMA, B-CELL; RIBAVIRIN; RITUXIMAB; VASCULITIS;

EID: 85017500055     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.02.010     Document Type: Review

References (97)

1. Ramos-Casals, M., Font, J., Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 17 (2005), 447–455.
2. Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Piette, J.C., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42 (1999), 2204–2212.
3. Pawlotsky, J.M., Roudot-Thoraval, F., Simmonds, P., Mellor, J., Ben Yahia, M.B., Andre, C., et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 122 (1995), 169–173.
4. Manns, M.P., Rambusch, E.G., Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 31 (1999), 39–42.
5. Zignego, A.L., Ferri, C., Pileri, S.A., Caini, P., Bianchi, F.B., Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 39 (2007), 2–17.
6. Terrier, B., Cacoub, P., Hepatitis C virus and lymphoma development. Hematol Rep, 2, 2010, p14.
7. Ferri, C., Antonelli, A., Mascia, M.T., Sebastiani, M., Fallahi, P., Ferrari, D., et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 39 (2007), 13–21.
8. Ramos-Casals, M., Trejo, O., García-Carrasco, M., Font, J., Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatol 42 (2003), 818–828.
9. Dammacco, F., Sansonno, D., Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 369 (2013), 1035–1045.
10. Cacoub, P., Terrier, B., Saadoun, D., Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis 73 (2014), 24–30.
11. Lam, B.P., Jeffers, T., Younoszai, Z., Fazel, Y., Younossi, Z.M., The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 8 (2015), 298–312.
12. Feld, J.J., Jacobson, I.M., Hezode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 373 (2015), 2599–2607.
13. Foster, G.R., Afdhal, N., Roberts, S.K., Brau, N., Gane, E.J., Pianko, S., et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 373 (2015), 2608–2617.
14. Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 373 (2015), 2618–2628.
15. Miller, M.H., Agarwal, K., Austin, A., Brown, A., Barclay, S.T., Dundas, P., et al. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 39 (2014), 1363–1375.
16. Mendez-Sanchez, N., Parana, R., Cheinquer, H., Alves de Mattos, A., Gadano, A., Silva, M., et al. Latin American Association for the Study of the Liver recommendations on treatment of hepatitis C. Ann Hepatol 13 (2014), s4–s66.
17. Puri, P., Anand, A.C., Saraswat, V.A., Acharya, S.K., Dhiman, R.K., Sarin, S.K., et al. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol 5 (2015), 221–238.
18. EASL Recommendations on Treatment of Hepatitis, C 2016. J Hepatol 66 (2017), 153–194.
19. Hepatitis C guidance. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
20. Jones, J., Hunter, D., Consensus methods for medical and health services research. BMJ 311 (1995), 376–380.
21. Ebell, M.H., Siwek, J., Weiss, B.D., Woolf, S.H., Susman, J., Ewigman, B., et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 69 (2004), 548–556.
22. Holmes, J.A., Thompson, A.J., Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 7 (2015), 51–70.
23. De Nicola, S., Aghemo, A., Campise, M.R., D'Ambrosio, R., Rumi, M.G., Messa, P., et al. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antivir Ther 19 (2014), 527–531.
24. Lim, L.Y., La, D., Cserti-gazdewich, C.M., Shah, H., Hpte, M., Lymphoma Remission by Interferon-Free HCV Eradication Without. Chemotherapy 3 (2015), 69–70.
25. Samain, A., Duval-Modeste, A.-B., Joly, P., Leblanc, C., Massy, N., Courville, P., et al. First case of drug rash eosinophilia and systemic symptoms due to boceprevir. J Hepatol 60 (2014), 891–893.
26. Urraro, T., Gragnani, L., Piluso, A., Fabbrizzi, A., Monti, M., Fognani, E., et al. Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. Case Reports Immunol 2015 (2015), 1–5.
27. Cornella, S.L., Stine, J.G., Kelly, V., Caldwell, S.H., Shah, N.L., Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med 5481 (2015), 1–5.
28. Gragnani, L., Fabbrizzi, A., Triboli, E., Urraro, T., Boldrini, B., Fognani, E., et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. Dig Liver Dis 46 (2014), 833–837.
29. Saadoun, D., Resche Rigon, M., Pol, S., Thibault, V., Blanc, F., Pialoux, G., et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 62 (2015), 24–30.
30. Sultanik, P., Klotz, C., Brault, P., Pol, S., Mallet, V., Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 125 (2015), 2446–2447.
31. Makara, M., Sulyok, M., Csacsovszki, O., Sulyok, Z., Valyi-Nagy, I., Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin: A case report. J Clin Virol 72 (2015), 66–68.
32. Sise, M.E., Bloom, A.K., Wisocky, J., Lin, M.V., Gustafson, J.L., Lundquist, A.L., et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63 (2016), 408–417.
33. Saadoun, D., Thibault, V., Si Ahmed, S.N., Alric, L., Mallet, M., Guillaud, C., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis, 2015, 1–6.
34. Sollima, S., Milazzo, L., Peri, A.M., Torre, A., Antinori, S., Galli, M., Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford), 2016.
35. Rossotti, R., Travi, G., Pazzi, A., Baiguera, C., Morra, E., Puoti, M., Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol 62 (2015), 234–237.
36. Misselwitz, B., Epprecht, J., Mertens, J., Biedermann, L., Scharl, M., Haralambieva, E., et al. Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection. Case Rep Gastroenterol 10 (2016), 108–114.
37. Pourmorteza, M., Tawadros, F., Bader, G., Al-Tarawneh, M., Cook, E., Shams, W., et al. Successful Treatment of Pyoderma Gangrenosum with Cryoglobulinemia and Hepatitis C. Am J Case Rep 17 (2016), 434–438.
38. Ortega-Garcia, M.P., Ortega-Gonzalez E (Trans.) Interferon-free treatment regimen for hepatitis C virus infection for extrahepatic manifestations: leukocytoclastic vasculitis Rev Esp Quimioter 29 (2016), 44–46.
39. Zaja, F., De Vita, S., Mazzaro, C., Sacco, S., Damiani, D., De Marchi, G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003), 3827–3834.
40. Sansonno, D., De Re, V., Lauletta, G., Tucci, F.A., Boiocchi, M., Dammacco, F., Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 (2003), 3818–3826.
41. Petrarca, A., Rigacci, L., Caini, P., Colagrande, S., Romagnoli, P., Vizzutti, F., et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 116 (2010), 335–342.
42. Visentini, M., Ludovisi, S., Petrarca, A., Pulvirenti, F., Zaramella, M., Monti, M., et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 10 (2011), 714–719.
43. Saadoun, D., Resche-Rigon, M., Sene, D., Perard, L., Karras, A., Cacoub, P., Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 67 (2008), 1431–1436.
44. Terrier, B., Saadoun, D., Sene, D., Sellam, J., Perard, L., Coppere, B., et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 60 (2009), 2531–2540.
45. Dammacco, F., Tucci, F.A., Lauletta, G., Gatti, P., De Re, V., Conteduca, V., et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116 (2010), 343–353.
46. Saadoun, D., Resche Rigon, M., Sene, D., Terrier, B., Karras, A., Perard, L., et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 116 (2010), 325–326.
47. Sneller, M.C., Hu, Z., Langford, C.A., A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 64 (2012), 835–842.
48. De Vita, S., Quartuccio, L., Isola, M., Mazzaro, C., Scaini, P., Lenzi, M., et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64 (2012), 843–853.
49. Visentini, M., Tinelli, C., Colantuono, S., Monti, M., Ludovisi, S., Gragnani, L., et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmun Rev 14 (2015), 889–896.
50. Quartuccio, L., Zuliani, F., Corazza, L., Scaini, P., Zani, R., Lenzi, M., et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. J Autoimmun 63 (2015), 88–93.
51. Roccatello, D., Sciascia, S., Baldovino, S., Rossi, D., Alpa, M., Naretto, C., et al. Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study. Am J Nephrol 43 (2016), 251–260.
52. Ferri, C., Cacoub, P., Mazzaro, C., Roccatello, D., Scaini, P., Sebastiani, M., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 11 (2011), 48–55.
53. Bonacci, M., Lens, S., Londono, M.-C., Marino, Z., Cid, M.C., Ramos-Casals, M., et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-acting Antivirals. Clin Gastroenterol Hepatol 15 (2017), 575–583.
54. Gragnani, L., Visentini, M., Fognani, E., Urraro, T., De Santis, A., Petraccia, L., et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 64 (2016), 1473–1482.
55. Cacoub, P., Comarmond, C., Domont, F., Savey, L., Saadoun, D., Cryoglobulinemia Vasculitis. Am J Med 128 (2015), 950–955.
56. Vannata, B., Arcaini, L., Zucca, E., Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?. Ther Adv Hematol 7 (2016), 94–107.
57. Cacoub, P., Comarmond, C., Domont, F., Savey, L., Desbois, A.C., Saadoun, D., Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 3 (2016), 3–14.
58. Nissen, M.J., Fontanges, E., Allam, Y., Zoulim, F., Trepo, C., Miossec, P., Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) 44 (2005), 1016–1020.
59. Isaacs, D., Abdelaziz, N., Keller, M., Tibble, J., Haq, I., Measuring the response of extrahepatic symptoms and quality of life to antiviral treatment in patients with hepatitis C. Hepat Res Treat, 2013, 2013, 910519.
60. Fadda, P., La Civita, L., Zignego, A.L., Ferri C (Trans.) Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome Reumatismo 54 (2002), 316–323.
61. Zuckerman, E., Keren, D., Rozenbaum, M., Toubi, E., Slobodin, G., Tamir, A., et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 18 (2000), 579–584.
62. Ramos-Casals, M., Stone, J.H., Cid, M.C., Bosch, X., The cryoglobulinaemias. Lancet 379 (2012), 348–360.
63. Tasleem, S., Sood, G.K., Hepatitis C associated B-cell non-hodgkin lymphoma: clinical features and the role of antiviral therapy. J Clin Transl Hepatol 3 (2015), 134–139.
64. Michot, J.-M., Canioni, D., Driss, H., Alric, L., Cacoub, P., Suarez, F., et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 90 (2015), 197–203.
65. Lin, R.J., Moskovits, T., Diefenbach, C.S., Hymes, K.B., Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C. Blood Cancer J, 6, 2016, e402.
66. Ramos-Casals, M., Muñoz, S., Medina, F., Jara, L.-J., Rosas, J., Calvo-Alen, J., et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 36 (2009), 1442–1448.
67. Doffoel-Hantz, V., Loustaud-Ratti, V., Ramos-Casals, M., Alain, S., Bezanahary, H., Liozon, E., et al. Evolution of Sjogren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin. Rev Med Interne 26 (2005), 88–94.
68. Chen, M.-H., Chen, M.-H., Tsai, C.-Y., Chou, C.-T., Lin, H.-Y., Huang, D.-F., et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus 24 (2015), 1029–1036.
69. Perlemuter, G., Cacoub, P., Sbai, A., Hausfater, P., Thibault, V., Le, T.H., et al. Hepatitis C virus infection in systemic lupus erythematosus: a case-control study. J Rheumatol 30 (2003), 1473–1478.
70. Onishi, S., Nagashima, T., Kimura, H., Matsuyama, Y., Yoshio, T., Minota, S., Systemic lupus erythematosus and Sjogren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus 19 (2010), 753–755.
71. Venezia, G., Licata, A., Di Marco, V., Craxi, A., Almasio, P.L., Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Dig Liver Dis 37 (2005), 882–885.
72. Ramos-Casals, M., Mana, J., Nardi, N., Brito-Zeron, P., Xaubet, A., Sanchez-Tapias, J.M., et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 84 (2005), 69–80.
73. Cacopardo, B., Benanti, F., Pinzone, M.R., Nunnari, G., Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature. BMC Res Notes, 6, 2013, 437.
74. Fernandez, I., Castellano, G., de Salamanca, R.E., Colina, F., Gomez de la Camara, A., Moran, M.J., et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 38 (2003), 314–319.
75. Furuta, M., Kaito, M., Gabazza, E., Fujita, N., Ishida, S., Tamaki, S., et al. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol 35 (2000), 60–62.
76. Esmail, E.S., Asal F-HE, Yussif M, Elfert AA. Low dose ribavirin has been effective in the treatment of incapacitating muco-cutaneous extrahepatic manifestations in patients with hepatitis C with contraindication or no access for approved antiviral treatment. Arab. J Gastroenterol 16 (2015), 125–128.
77. Bladowska, J., Zimny, A., Knysz, B., Malyszczak, K., Koltowska, A., Szewczyk, P., et al. Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: a pilot study. J Hepatol 59 (2013), 651–657.
78. Monaco, S., Mariotto, S., Ferrari, S., Calabrese, M., Zanusso, G., Gajofatto, A., et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. World J Gastroenterol 21 (2015), 11974–11983.
79. Spiegel, B.M.R., Younossi, Z.M., Hays, R.D., Revicki, D., Robbins, S., Kanwal, F., Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41 (2005), 790–800.
80. Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.C., Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 10 (2006), 1–113 [iii].
81. Neary, M.P., Cort, S., Bayliss, M.S., Ware, J.E.J., Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 19 (1999), 77–85.
82. Thein, H.H., Maruff, P., Krahn, M.D., Kaldor, J.M., Koorey, D.J., Brew, B.J., et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med 8 (2007), 520–528.
83. Younossi, Z.M., Stepanova, M., Henry, L., Nader, F., Hunt, S., An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. Am J Gastroenterol 111 (2016), 808–816.
84. Ramos-Casals, M., Forns, X., Brito-Zeron, P., Vargas, A., Ruiz, M., Laguno, M., et al. Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. J Viral Hepat 14 (2007), 736–742.
85. Boglione, L., Cusato, J., Allegra, S., Cariti, G., Di Perri, G., D'Avolio, A., Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. Arch Virol 160 (2015), 2009–2017.
86. Sansonno, D., Russi, S., Serviddio, G., Conteduca, V., D'Andrea, G., Sansonno, L., et al. Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis. J Rheumatol 41 (2014), 91–98.
87. Pietrogrande, M., De Vita, S., Zignego, A.L., Pioltelli, P., Sansonno, D., Sollima, S., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 10 (2011), 444–454.
88. Retamozo, S., Brito-Zeron, P., Bosch, X., Stone, J.H., Ramos-Casals, M., Cryoglobulinemic disease. Oncology 27 (2013), 1098–1105.
89. Giuggioli, D., Sebastiani, M., Colaci, M., Fallahi, P., Gragnani, L., Zignego, A.L., et al. Treatment of HCV-related mixed cryoglobulinemia. Curr Drug Targets, 2015.
90. Retamozo, S., Diaz-Lagares, C., Bosch, X., Bove, A., Brito-Zeron, P., Gomez, M.-E., et al. Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. Medicine (Baltimore), 2013.
91. Hausfater, P., Cacoub, P., Assogba, U., Lebon, P., Piette, J.C., Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron 91 (2002), 627–630 doi: 65023.
92. Sene, D., Ghillani-Dalbin, P., Amoura, Z., Musset, L., Cacoub, P., Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 60 (2009), 3848–3855.
93. Younossi, Z., Park, H., Henry, L., Adeyemi, A., Stepanova, M., Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 150 (2016), 1599–1608.
94. Ferri, C., Ramos-Casals, M., Zignego, A.L., Arcaini, L., Roccattello, D., Antonelli, A., International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev, 2016 [In press].
95. Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M., Marcellin, P., Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36 (2016), 47–57.
96. Ghetie, D., Mehraban, N., Sibley, C.H., Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum Dis Clin North Am 41 (2015), 93–108 [viii–ix].
97. Gentile, I., Maraolo, A.E., Niola, M., Graziano, V., Borgia, G., Paternoster, M., Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Rev Gastroenterol Hepatol 10 (2016), 1227–1234.